{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T18:56:47Z","timestamp":1776538607779,"version":"3.51.2"},"reference-count":86,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"J & J","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clovis"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tesaro"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Caris"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takeda"},{"name":"Roche\/Genentech"},{"name":"Janssen"},{"name":"OncoMed"},{"name":"Esperance"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013223","name":"PTC Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1093\/annonc\/mdz104","type":"journal-article","created":{"date-parts":[[2019,3,16]],"date-time":"2019-03-16T05:29:34Z","timestamp":1552714174000},"page":"721-732","source":"Crossref","is-referenced-by-count":67,"title":["Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option"],"prefix":"10.1016","volume":"30","author":[{"given":"M.","family":"Buechel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-0156","authenticated-orcid":false,"given":"S.N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdz104_bb0010","unstructured":"American Cancer Society. Cancer Facts and Figures 2018. Atlanta, GA 2018. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2018.html."},{"issue":"3","key":"10.1093\/annonc\/mdz104_bb0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2016.03.005","article-title":"Moving beyond the platinum sensitive\/resistant paradigm for patients with recurrent ovarian cancer","volume":"141","author":"Alvarez","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdz104_bb0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdz104_bb0025","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"issue":"12","key":"10.1093\/annonc\/mdz104_bb0030","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz104_bb0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2014.09.017","article-title":"Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial","volume":"136","author":"Lee","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdz104_bb0040","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/bjc.2011.328","article-title":"Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort","volume":"105","author":"Zang","year":"2011","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdz104_bb0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdz104_bb0050","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"Bois","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz104_bb0055","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdz104_bb0060","doi-asserted-by":"crossref","first-page":"5501.","DOI":"10.1200\/JCO.2018.36.15_suppl.5501","volume":"36","author":"Coleman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz104_bb0065","series-title":"International Gynecologic Cancer Society","article-title":"A phase III randomized controlled trial of secondary cytoreductive surgery (SCS) followed by platinum-based chemotherapy (PC) platinum-sensitive, recurrent ovarian cancer (PSOC)\u2014surgical parameters","author":"Coleman","year":"2018"},{"issue":"3","key":"10.1093\/annonc\/mdz104_bb0070","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminoncol.2017.08.004","article-title":"Guidance statement on BRCA1\/2 tumor testing in ovarian cancer patients","volume":"44","author":"Capoluongo","year":"2017","journal-title":"Semin Oncol"},{"issue":"26","key":"10.1093\/annonc\/mdz104_bb0075","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1093\/annonc\/mdz104_bb0080","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","article-title":"Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study","volume":"35","author":"Pignata","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdz104_bb0085","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.clon.2018.01.008","article-title":"Trabectedin in ovarian cancer: is it now a standard of care?","volume":"30","author":"Ventriglia","year":"2018","journal-title":"Clin Oncol (R Coll Radiol"},{"issue":"8","key":"10.1093\/annonc\/mdz104_bb0090","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/91008","article-title":"Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair","volume":"7","author":"Takebayashi","year":"2001","journal-title":"Nat Med"},{"issue":"3","key":"10.1093\/annonc\/mdz104_bb0095","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1039\/b808331m","article-title":"Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem","volume":"26","author":"Cuevas","year":"2009","journal-title":"Nat Prod Rep"},{"issue":"1","key":"10.1093\/annonc\/mdz104_bb0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/mdq352","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial","volume":"22","author":"Poveda","year":"2011","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz104_bb0105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","article-title":"Latest research and treatment of advanced-stage epithelial ovarian cancer","volume":"10","author":"Coleman","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"10.1093\/annonc\/mdz104_bb0110","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10023","key":"10.1093\/annonc\/mdz104_bb0115","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"issue":"15","key":"10.1093\/annonc\/mdz104_bb0120","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1093\/annonc\/mdz104_bb0125","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1093\/annonc\/mdz104_bb0130","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10106","key":"10.1093\/annonc\/mdz104_bb0135","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1093\/annonc\/mdz104_bb0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0304-3835(94)90412-X","article-title":"Three-dimensional modelling of tumor-induced ovarian angiogenesis","volume":"87","author":"Schoenfeld","year":"1994","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1093\/annonc\/mdz104_bb0145","first-page":"33","article-title":"Tumor angiogenesis in advanced stage ovarian carcinoma","volume":"147","author":"Hollingsworth","year":"1995","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1093\/annonc\/mdz104_bb0150","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1097-0215(19960621)69:3<205::AID-IJC10>3.0.CO;2-6","article-title":"Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas","volume":"69","author":"Gasparini","year":"1996","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdz104_bb0155","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00004347-199707000-00011","article-title":"The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer","volume":"16","author":"Nakanishi","year":"1997","journal-title":"Int J Gynecol Pathol"},{"issue":"6","key":"10.1093\/annonc\/mdz104_bb0160","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jnci\/90.6.447","article-title":"Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice","volume":"90","author":"Yoneda","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdz104_bb0165","first-page":"587","article-title":"The prognostic significance of angiogenesis in epithelial ovarian carcinoma","volume":"5","author":"Alvarez","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1093\/annonc\/mdz104_bb0170","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0002-9440(10)64079-5","article-title":"Molecular determinants of ovarian cancer plasticity","volume":"158","author":"Sood","year":"2001","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1093\/annonc\/mdz104_bb0175","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/mp.55.6.348","article-title":"Angiogenesis in epithelian ovarian cancer","volume":"55","author":"Bamberger","year":"2002","journal-title":"Mol Pathol"},{"issue":"2","key":"10.1093\/annonc\/mdz104_bb0180","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11912-002-0078-z","article-title":"Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies","volume":"4","author":"Paley","year":"2002","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"10.1093\/annonc\/mdz104_bb0185","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1158\/1078-0432.CCR-04-1148","article-title":"Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas","volume":"11","author":"Ueda","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1093\/annonc\/mdz104_bb0190","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.2006.08.8583","article-title":"Tumor vascular proteins as biomarkers in ovarian cancer","volume":"25","author":"Buckanovich","year":"2007","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1093\/annonc\/mdz104_bb0195","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.2007.11.1088","article-title":"Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition","volume":"25","author":"Martin","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5\u20136","key":"10.1093\/annonc\/mdz104_bb0200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1155\/2007\/257602","article-title":"Markers of angiogenesis in ovarian cancer","volume":"23","author":"Merritt","year":"2007","journal-title":"Dis Markers"},{"issue":"5","key":"10.1093\/annonc\/mdz104_bb0205","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/CCO.0b013e32827035f0","article-title":"Antiangiogenic therapy for ovarian cancer","volume":"19","author":"Rosa","year":"2007","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz104_bb0210","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/ncponc1051","article-title":"Angiogenesis as a strategic target for ovarian cancer therapy","volume":"5","author":"Spannuth","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdz104_bb0215","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","article-title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Monk","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdz104_bb0220","doi-asserted-by":"crossref","first-page":"viii3332","DOI":"10.1093\/annonc\/mdy285.142","article-title":"Carboplatin\/pegylated liposomal doxorubicin\/bevacizumab (CD-BEV) vs. carboplatin\/gemcitabine\/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer","volume":"29","author":"Pfisterer","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz104_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"5","key":"10.1093\/annonc\/mdz104_bb0230","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1093\/annonc\/mdz104_bb0235","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz104_bb0240","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10, 000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdz104_bb0245","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/annonc\/mdw374.18","article-title":"Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC)","volume":"27","author":"Infante","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdz104_bb0250","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.5510","article-title":"Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study","volume":"33","author":"Varga","year":"2015","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1093\/annonc\/mdz104_bb0255","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz104_bb0260","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/0008-5472.CAN-12-2225","article-title":"Dose-dense chemotherapy improves mechanisms of antitumor immune response","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res"},{"issue":"4","key":"10.1093\/annonc\/mdz104_bb0265","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1078-0432.CCR-16-1433","article-title":"Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy","volume":"23","author":"Lo","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1093\/annonc\/mdz104_bb0270","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res"},{"issue":"7","key":"10.1093\/annonc\/mdz104_bb0275","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/sj.bjc.6602476","article-title":"The role of dendritic cell precursors in tumour vasculogenesis","volume":"92","author":"Coukos","year":"2005","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdz104_bb0280","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/bjc.2012.468","article-title":"VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2","volume":"107","author":"Gavalas","year":"2012","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdz104_bb0285","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.4049\/jimmunol.178.3.1505","article-title":"Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy","volume":"178","author":"Bouzin","year":"2007","journal-title":"J Immunol"},{"issue":"15","key":"10.1093\/annonc\/mdz104_bb0290","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res"},{"issue":"24","key":"10.1093\/annonc\/mdz104_bb0295","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1093\/annonc\/mdz104_bb0300","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz104_bb0305","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10637-011-9682-9","article-title":"Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study","volume":"30","author":"Samol","year":"2012","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1093\/annonc\/mdz104_bb0310","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/bjc.2011.8","article-title":"A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours","volume":"104","author":"Khan","year":"2011","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdz104_bb0315","doi-asserted-by":"crossref","first-page":"R88","DOI":"10.1186\/bcr3484","article-title":"Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer","volume":"15","author":"Dent","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"8","key":"10.1093\/annonc\/mdz104_bb0320","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-11-2425","article-title":"A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors","volume":"18","author":"Rajan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"9737","key":"10.1093\/annonc\/mdz104_bb0325","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"issue":"15","key":"10.1093\/annonc\/mdz104_bb0330","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-2796","article-title":"A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1\/2-mutated ovarian carcinoma or other solid tumors","volume":"23","author":"Kristeleit","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1093\/annonc\/mdz104_bb0335","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz104_bb0340","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz104_bb0345","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1200\/JCO.2018.36.15_suppl.5514","article-title":"QUADRA: a phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received \u22653 prior chemotherapy regimens","volume":"36","author":"Moore","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz104_bb0350","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly(ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdz104_bb0355","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/nm.3369","article-title":"Mechanisms of resistance to therapies targeting BRCA-mutant cancers","volume":"19","author":"Lord","year":"2013","journal-title":"Nat Med"},{"issue":"9","key":"10.1093\/annonc\/mdz104_bb0360","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdz104_bb0365","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ygyno.2015.03.042","volume":"137","author":"Coleman","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz104_bb0370","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/bjc.2011.555","article-title":"Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours","volume":"106","author":"Dean","year":"2012","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1093\/annonc\/mdz104_bb0375","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.ejca.2013.05.020","article-title":"A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer","volume":"49","author":"Liu","year":"2013","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdz104_bb0380","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdz104_bb0385","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx372.024","article-title":"953PA phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovarian cancer (ENGOT-OV24\/AVANOVA1","volume":"28","author":"Mirza","year":"2017","journal-title":"Ann Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz104_bb0390","article-title":"Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17","volume":"36","author":"Pignata","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 9","key":"10.1093\/annonc\/mdz104_bb0395","article-title":"Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1\/2 mutation (BRCAm): phase III SOLO1 trial","volume":"29","author":"Moore","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdz104_bb0400","unstructured":"FDA approves olaparib for first-line maintenance of BRCA-mutated advanced ovarian cancer. 2018. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm628876.htm."},{"key":"10.1093\/annonc\/mdz104_bb0405","unstructured":"Merck KGaA, Darmstadt, Germany, and Pfizer provide update on JAVELIN ovarian 100 trial of avelumab in previously untreated advanced ovarian cancer. 2018. https:\/\/investors.pfizer.com\/investor-news\/press-release-details\/2018\/Merck-KGaA-Darmstadt-Germany-and-Pfizer-Provide-Update-on-JAVELIN-Ovarian-100-Trial-of-Avelumab-in-Previously-Untreated-Advanced-Ovarian-Cancer\/default.aspx."},{"issue":"9375","key":"10.1093\/annonc\/mdz104_bb0410","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"issue":"29","key":"10.1093\/annonc\/mdz104_bb0415","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz104_bb0420","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdz104_bb0425","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"13","key":"10.1093\/annonc\/mdz104_bb0430","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1093\/annonc\/mdz104_bb0435","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419311767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419311767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz104\/28566108\/mdz104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz104\/28566849\/mdz104.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/5\/721\/28771001\/mdz104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:58:47Z","timestamp":1624697927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419311767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":86,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0923753419311767"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz104","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}